CR11304A - Metodos, composiciones farmaceuticas y articulos de manufactura para la administracion de celulas terapeuticas al sistema nervioso aniimal - Google Patents

Metodos, composiciones farmaceuticas y articulos de manufactura para la administracion de celulas terapeuticas al sistema nervioso aniimal

Info

Publication number
CR11304A
CR11304A CR11304A CR11304A CR11304A CR 11304 A CR11304 A CR 11304A CR 11304 A CR11304 A CR 11304A CR 11304 A CR11304 A CR 11304A CR 11304 A CR11304 A CR 11304A
Authority
CR
Costa Rica
Prior art keywords
cns
methods
articles
administration
manufacture
Prior art date
Application number
CR11304A
Other languages
English (en)
Inventor
H Frey Ii William
Danielyan Lusine
H Gleiter Christoph
Original Assignee
H Frey Ii William
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Frey Ii William filed Critical H Frey Ii William
Publication of CR11304A publication Critical patent/CR11304A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

Esta invencion se dirige, entre otras cosas, a la prevencion y/o al tratamiento del sistema nervioso central danado y/o en degeneracion debido a una enfermedad u otra condicion que causa la perdida o la muerte de las celulas del SNC.
CR11304A 2007-09-11 2010-03-09 Metodos, composiciones farmaceuticas y articulos de manufactura para la administracion de celulas terapeuticas al sistema nervioso aniimal CR11304A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97128407P 2007-09-11 2007-09-11
US12/109,066 US8283160B2 (en) 2007-09-11 2008-04-24 Methods, pharmaceutical compositions and articles of manufacture for administering therapeutic cells to the animal central nervous system

Publications (1)

Publication Number Publication Date
CR11304A true CR11304A (es) 2010-05-03

Family

ID=40432083

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11304A CR11304A (es) 2007-09-11 2010-03-09 Metodos, composiciones farmaceuticas y articulos de manufactura para la administracion de celulas terapeuticas al sistema nervioso aniimal

Country Status (24)

Country Link
US (3) US8283160B2 (es)
EP (1) EP2200621B1 (es)
JP (2) JP5600294B2 (es)
KR (2) KR20150039197A (es)
CN (2) CN101801397A (es)
AT (1) ATE554778T1 (es)
AU (1) AU2008299124B2 (es)
BR (1) BRPI0816325B8 (es)
CA (1) CA2696892C (es)
CR (1) CR11304A (es)
CY (1) CY1113120T1 (es)
DK (1) DK2200621T3 (es)
ES (1) ES2388403T3 (es)
HR (1) HRP20120560T1 (es)
IL (1) IL204371A (es)
MX (1) MX2010002738A (es)
MY (1) MY154061A (es)
PL (1) PL2200621T3 (es)
PT (1) PT2200621E (es)
RU (1) RU2468818C2 (es)
SG (1) SG184724A1 (es)
SI (1) SI2200621T1 (es)
UA (1) UA98507C2 (es)
WO (1) WO2009035901A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8518390B2 (en) * 2003-06-27 2013-08-27 Advanced Technologies And Regenerative Medicine, Llc Treatment of stroke and other acute neural degenerative disorders via intranasal administration of umbilical cord-derived cells
US8283160B2 (en) 2007-09-11 2012-10-09 Frey Ii William H Methods, pharmaceutical compositions and articles of manufacture for administering therapeutic cells to the animal central nervous system
EP2153844A1 (en) * 2008-08-14 2010-02-17 HAUBECK, Hans-Dieter Human hyaluronidases for axonal regrowth
KR20240052847A (ko) 2008-08-20 2024-04-23 셀룰래리티 인코포레이티드 개선된 세포 조성물 및 그의 제조 방법
US8609088B2 (en) 2011-05-10 2013-12-17 Regents Of The University Of Minnesota Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases
US8387798B1 (en) 2012-04-27 2013-03-05 Abdulmohsen E. A. H. Al-Terki Mutiple oral and nasal surgical procedures method and kit
US10022083B2 (en) 2011-06-02 2018-07-17 Abdulmohsen E. A. H. Al-Terki Multiple oral and nasal surgical procedures method and kit
US9821149B2 (en) * 2011-10-14 2017-11-21 Healthpartners Research & Education Methods for using ultrasound for enhancing efficiency and targeting of intranasal administration of therapeutic compounds to the central nervous system
CN104837987B (zh) 2011-12-23 2018-10-02 德普伊新特斯产品公司 人脐带组织来源的细胞的检测
US20130336928A1 (en) * 2012-06-18 2013-12-19 Healthpartners Research & Education Methods and pharmaceutical compositions for treatment of central nervous system disorders with therapeutic agent(s) in patients with concurrent non-cns condition(s) or disorders contraindicating systemic administration of the therapeutic agent(s)
FR3001974B1 (fr) 2013-02-08 2016-02-12 Olivier Schussler Procede de purification de cellules
RU2522816C1 (ru) * 2013-02-12 2014-07-20 Российская Федерация, от имени которой выступает Министерство промышленности и торговли Российской Федерации (Минпромторг России) Композиция для клеточно-заместительной терапии дефектов мягких тканей
US10279012B2 (en) * 2013-03-11 2019-05-07 Healthpartners Research & Education Methods of treating and preventing social communication disorder in patients by intranasal administration of insulin
CN115120745A (zh) 2013-05-15 2022-09-30 明尼苏达大学董事会 腺相关病毒介导的基因向中枢神经系统转移
AU2015211021B2 (en) 2014-01-28 2020-07-02 Buck Institute For Research On Aging Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
WO2015116735A1 (en) 2014-01-28 2015-08-06 Mayo Foundation For Medical Education And Research Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders
CA2942172A1 (en) * 2014-03-06 2015-09-11 Children's National Medical Center Treatment of neonatal brain injury with hb-egf
US11413408B2 (en) 2014-07-29 2022-08-16 Peter Edenhoffer Positive pressure inspiration device for delivery of medicaments
CA2956447C (en) * 2014-07-29 2023-04-11 Peter EDENHOFFER Positive pressure inspiration device for delivery of medicaments
US10130657B2 (en) 2015-02-13 2018-11-20 John C. Hughes Formulation, apparatus, and methods for treatment of brain trauma
US10335435B2 (en) 2015-05-22 2019-07-02 Marco Merida Method for endoscopically delivering stem cells to the brain using an intranasal, injectable approach
US20160361253A1 (en) * 2015-06-13 2016-12-15 Noveome Biotherapeutics, Inc. Novel Methods for Delivering Therapeutic Agents to the Eye via Nasal Passages
WO2017011326A1 (en) 2015-07-10 2017-01-19 Sanjay Gupta Nasal foam via cribriform plate for medication delivery to the brain and/or body and for nasal moisturization and hygiene
CN116196995A (zh) 2015-08-13 2023-06-02 武田药品工业株式会社 用于评估接触系统激活的含有蛋白酶抑制剂的真空采血管
IL305449A (en) 2016-04-15 2023-10-01 Univ Pennsylvania Gene therapy for the treatment of type II mucositis
CN106924286A (zh) * 2017-02-16 2017-07-07 上海安集协康生物技术股份有限公司 一种经鼻腔给药用于帕金森病治疗的神经干细胞制剂
CN108732355B (zh) * 2017-04-25 2021-06-25 首都医科大学附属北京安定医院 一种测定bace1酶切nrg1活性的检测方法及其试剂盒
US20190060109A1 (en) * 2017-08-31 2019-02-28 Gregory Todd Johnson Method of Preventing Traumatic Brain Injury (TBI)
CA3076036A1 (en) 2017-09-22 2019-03-28 The Trustees Of The University Of Pennsylvania Gene therapy for treating mucopolysaccharidosis type ii
CN108096280A (zh) * 2017-12-28 2018-06-01 上海安集协康生物技术股份有限公司 一种神经干细胞滴鼻剂
KR20220005900A (ko) * 2020-07-07 2022-01-14 가톨릭대학교 산학협력단 뇌신경계질환 예방 또는 치료용 약학적 조성물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624898A (en) * 1989-12-05 1997-04-29 Ramsey Foundation Method for administering neurologic agents to the brain
US20040266715A1 (en) * 1999-03-31 2004-12-30 Wong Liang Fong Neurite regeneration
US6667176B1 (en) * 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
AU2049500A (en) * 1998-12-09 2000-06-26 Chiron Corporation Administration of neurotrophic agents to the central nervous system
CN100425287C (zh) * 1999-02-09 2008-10-15 理化学研究所 肿瘤疫苗
US6749850B1 (en) * 1999-08-18 2004-06-15 The General Hospital Corporation Methods, compositions and kits for promoting recovery from damage to the central nervous system
US20020169102A1 (en) * 2001-04-03 2002-11-14 Frey William H. Intranasal delivery of agents for regulating development of implanted cells in the CNS
JP3886346B2 (ja) * 2001-06-22 2007-02-28 サンバイオ，インコーポレイティド 骨髄間質細胞由来Ｓｃｈｗａｎｎ細胞を含む神経再生用医薬組成物
EP1438942A1 (en) * 2003-01-17 2004-07-21 Schering Oy An otorhinological drug delivery device
JP4676442B2 (ja) * 2003-12-02 2011-04-27 セラヴィー バイオサイエンシズ エルエルシー 神経前駆細胞を増殖させるための組成物および方法
WO2007002664A2 (en) * 2005-06-22 2007-01-04 Massachusetts Institute Of Technology Propagation of undifferentiated embryonic stem cells in hyaluronic acid hydrogel
US9456979B2 (en) * 2006-04-27 2016-10-04 Sri International Adminstration of intact mammalian cells to the brain by the intranasal route
US8168169B2 (en) * 2006-08-09 2012-05-01 Mclean Hospital Corporation Methods and compositions for the treatment of medical disorders
US8283160B2 (en) 2007-09-11 2012-10-09 Frey Ii William H Methods, pharmaceutical compositions and articles of manufacture for administering therapeutic cells to the animal central nervous system

Also Published As

Publication number Publication date
KR20100094450A (ko) 2010-08-26
MY154061A (en) 2015-04-30
AU2008299124A1 (en) 2009-03-19
RU2468818C2 (ru) 2012-12-10
KR20150039197A (ko) 2015-04-09
WO2009035901A1 (en) 2009-03-19
IL204371A (en) 2015-02-26
EP2200621A4 (en) 2011-03-16
CA2696892C (en) 2016-05-17
JP5600294B2 (ja) 2014-10-01
BRPI0816325A2 (pt) 2015-03-24
US20160206554A1 (en) 2016-07-21
BRPI0816325B8 (pt) 2021-05-25
DK2200621T3 (da) 2012-08-06
US8283160B2 (en) 2012-10-09
HRP20120560T1 (hr) 2012-08-31
PL2200621T3 (pl) 2012-10-31
EP2200621A1 (en) 2010-06-30
CY1113120T1 (el) 2016-04-13
BRPI0816325B1 (pt) 2020-04-22
CA2696892A1 (en) 2009-03-19
RU2010113932A (ru) 2011-10-20
JP2014098051A (ja) 2014-05-29
SI2200621T1 (sl) 2012-09-28
MX2010002738A (es) 2010-08-04
SG184724A1 (en) 2012-10-30
JP2010539084A (ja) 2010-12-16
AU2008299124B2 (en) 2013-07-04
CN103181932A (zh) 2013-07-03
PT2200621E (pt) 2012-07-31
US20090068155A1 (en) 2009-03-12
UA98507C2 (ru) 2012-05-25
CN101801397A (zh) 2010-08-11
US20130028874A1 (en) 2013-01-31
KR101504110B1 (ko) 2015-03-19
US9445991B2 (en) 2016-09-20
ATE554778T1 (de) 2012-05-15
EP2200621B1 (en) 2012-04-25
ES2388403T3 (es) 2012-10-15

Similar Documents

Publication Publication Date Title
CR11304A (es) Metodos, composiciones farmaceuticas y articulos de manufactura para la administracion de celulas terapeuticas al sistema nervioso aniimal
AU2018256602A1 (en) Functionalized benzamide derivatives as antiviral agents against hbv infection
PH12017501185A1 (en) Compounds, compositions and methods useful for cholesterol mobilisation
BR112012021086A2 (pt) composições farmacêuticas de composto espiro-oxindole para administração tópica e seu uso como agentes terapêuticos
MA35431B1 (fr) Composition antiparasitaires comprenant un agent actif d'isoxazoline procedes et utilisations associes
BR112013002112A2 (pt) composto, composição farmacêutica, e, uso de um composto, ou de um respectivo sal farmaceuticamente aceitável ou n-óxido, ou um solvato ou hidrato do mesmo, ou de uma composição
BRPI1011657A2 (pt) derivados aminopropiônicos substituídos como inibidores de neprilisina
BR112013001125A2 (pt) compostos inibidores de rho cinase bifuncionais, composição e uso
WO2012078593A3 (en) Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis
ATE555099T1 (de) Dual wirkende benzimidazol-derivate und deren verwendung als blutdrucksenkende mittel
GEP20125624B (en) Pyridazine derivatives as smo inhibitors
BR112013011580A2 (pt) derivados de ácido bisfenil pentanoico substituído por amino como inibidores de nep
CL2007003356A1 (es) Compuestos derivados de benzopirazoles; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para el tratamiento del asma, inflamacion, entre otras enfermedades.
HK1135923A1 (en) Pharmaceutical agent having long-lasting effect of treating arthritic disorders
WO2009109654A8 (en) 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, and cx3cr1
WO2012162439A3 (en) Compositions comprising fusidic acid and packages therefor
WO2010005580A3 (en) Methods and compositions of small molecule modulators of hepatocyte growth factor (scatter factor) activity
WO2009038412A3 (en) Beta-secretase inhibiting compounds
MX2013008197A (es) Sales de aminas organicas de azilsartan, metodo de preparacion y uso de las mismas.
UY30847A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
CL2007003120A1 (es) Uso de una cantidad terapeuticamente eficaz de compuestos derivados de acido carbamico sustituidos y otro agente activo, para el tratamiento de la depresion.
BRPI0620983B8 (pt) uso de derivados de triazina para fabricação de um medicamento, e composição farmacêutica para uso tópico
MY182553A (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
WO2009092892A3 (fr) Nouvelle composition pour traiter les effets secondaires des traitements anticancereux
WO2009038411A3 (en) Beta-secretase inhibiting compounds having oxo-dihydro-pyrazole moiety